Nope. I am completely correct. Check the filings plus check the BIO CEO presentation.
17 million FULLY DILUTED shares.
6 million OUTSTANDING shares.
Yes, fully diluted.
However, there are only 6 million outstanding.
No way they sign up for a conference to release results on a Monday.....just to release bad results.
IMO.....Do your own DD.
And with 6 million shares outstanding......it wont be just a bump.
Have you read their BIO CEO presentation? Its on the FRONT PAGE of their website. Read it. 2nd to last slide.
The company is actually very transparent about it if you bother to read what they provide.
They had 4.8mil shares outstanding and 17mil fully diluted.....INCLUDING THE PREFERRED, before these preferred shares were converted. Now they have 6 million shares outstanding and STILL 17 Mil fully diluted.
People should really learn the facts and THEN post.........not the other way around.
Oh, I see. You are one of those people who troll message boards faking an attempt at discussion, when in reality you are just looking for a way for you to TRY (key word here) to make yourself look intelligent by putting down anything anyone says, good point or not.
I was wondering why noone would engage you. Now I know.
"science tells us what is potentially safe and unsafe"
Yes, potentially being the key word there. Preclinical data tells us what to move to the clinic. Unfortunately for biotechnology and pharma companies this only translates to a marketable drug just over 10% of the time. Most of the failures are do to safety issues not seen in the lab or models. Any CEO worth a #$%$ knows this and will minimize the risking risk of failure. Choosing a delivery vehicle with hundreds of HUMAN clinical SAFETY data points over one with nice lab data is a good way to minimize this risk.
An RNAi or mRNA therapeutic company goes looking for a delivery company to partner with. They test them all in the lab. The company with the most experience and thus the most HUMAN safety data will be given the most weight.
When spending tens if not hundreds of millions on clinical trials would a company choose a delivery vehicle with hundreds of HUMAN clinical SAFETY data points or a delivery vehicle with lab data?
Don't underestimate Tekmira 's existing HUMAN SAFETY data.
You misunderstood.....I dont own it. I successfully traded it a couple of time but wasnt in during this pop. I was just checking in, saw you posted and recognized you from years back.
Good luck to you as well!
tagetlocman!!! Good to see you back here. Just checking in.
You used to be a long, and now you are bashing. Trying to get back in my friend? :~)
I am surprised this keeps on going up. Its usually a pop and drop. Maybe this time is different with Lockheed RUNNING THE ENTIRE SHOW down under?
I assume you meant it should be rising into Phase2 results in March? Unless you plan on holding through phase 3 that is.
Nice one. Another high patient population where there are no good options out there, with easy to measure end-points, meaning quick through the clinical trials.
Well done management.
If you listened to the webcast yesterday, it is plain to see that LJPC is not going after the NASH indication. There are no timelines for clinical trials, and when asked he said that they chose CKD over NASH because CKD has direct, easy and quickly measure end-point while NASH does not.